Meet The Company Creating Novel Products For The Treatment Of ADHD

Sign up for this week’s All Access giveaway here

Shane Schaffer, CEO of Cingulate, Inc. CING, was a guest on Benzinga’s All Access on August 22, 2022.

Cingulate is a clinical stage biopharmaceutical company focused on the development of innovative new product candidates for the treatments of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety associated disorders.

Watch the full interview here:

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.


 

Posted In: Benzinga All AccessBiotechPenny StocksInterviewGeneral